|
US5208036A
(en)
|
1985-01-07 |
1993-05-04 |
Syntex (U.S.A.) Inc. |
N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US5143854A
(en)
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
|
US5279833A
(en)
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
|
US5283185A
(en)
|
1991-08-28 |
1994-02-01 |
University Of Tennessee Research Corporation |
Method for delivering nucleic acids into cells
|
|
US5412087A
(en)
|
1992-04-24 |
1995-05-02 |
Affymax Technologies N.V. |
Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
|
|
ATE219660T1
(de)
|
1994-09-30 |
2002-07-15 |
Inex Pharmaceuticals Corp |
Mittel zum einbringen polyanionischer materialien in zellen
|
|
US5753613A
(en)
|
1994-09-30 |
1998-05-19 |
Inex Pharmaceuticals Corporation |
Compositions for the introduction of polyanionic materials into cells
|
|
ATE544776T1
(de)
|
1994-12-29 |
2012-02-15 |
Massachusetts Inst Technology |
Chimäre dna-bindeproteine
|
|
US5695937A
(en)
|
1995-09-12 |
1997-12-09 |
The Johns Hopkins University School Of Medicine |
Method for serial analysis of gene expression
|
|
US7368551B2
(en)
|
1998-06-25 |
2008-05-06 |
The General Hospital Corporation |
De novo DNA cytosine methyltransferase genes, polypeptides and uses thereof
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
EP1276859B1
(en)
|
2000-04-28 |
2007-02-07 |
Sangamo Biosciences Inc. |
Targeted modification of chromatin structure
|
|
US6919204B2
(en)
|
2000-09-29 |
2005-07-19 |
Sangamo Biosciences, Inc. |
Modulation of gene expression using localization domains
|
|
US7273923B2
(en)
|
2001-01-22 |
2007-09-25 |
Sangamo Biosciences, Inc. |
Zinc finger proteins for DNA binding and gene regulation in plants
|
|
CA2461290C
(en)
|
2001-09-24 |
2014-11-25 |
Sangamo Biosciences, Inc. |
Modulation of stem cells using zinc finger proteins
|
|
AU2003219847A1
(en)
|
2002-02-21 |
2003-09-09 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for reversibly controlling expression of target genes in cells
|
|
CA2539439C
(en)
|
2003-09-19 |
2012-10-23 |
Sangamo Biosciences, Inc. |
Engineered zinc finger proteins for regulation of gene expression
|
|
US20070192880A1
(en)
|
2003-10-03 |
2007-08-16 |
University Of Rochester |
Horming response element binding transregulators
|
|
US7745651B2
(en)
|
2004-06-07 |
2010-06-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use
|
|
CA2597724A1
(en)
|
2005-02-14 |
2007-08-02 |
Sirna Therapeutics, Inc. |
Cationic lipids and formulated molecular compositions containing them
|
|
EP3100718B1
(en)
|
2008-01-02 |
2019-11-27 |
Arbutus Biopharma Corporation |
Improved compositions and methods for the delivery of nucleic acids
|
|
EP2279254B1
(en)
|
2008-04-15 |
2017-07-05 |
Protiva Biotherapeutics Inc. |
Novel lipid formulations for nucleic acid delivery
|
|
WO2010108126A2
(en)
|
2009-03-19 |
2010-09-23 |
Fate Therapeutics, Inc. |
Reprogramming compositions and methods of using the same
|
|
US20110071208A1
(en)
|
2009-06-05 |
2011-03-24 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated dicer-substrate interfering rna
|
|
ES2613498T3
(es)
|
2009-07-01 |
2017-05-24 |
Protiva Biotherapeutics Inc. |
Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
|
|
US8450107B1
(en)
|
2011-11-30 |
2013-05-28 |
The Broad Institute Inc. |
Nucleotide-specific recognition sequences for designer TAL effectors
|
|
ES2728782T3
(es)
|
2012-05-25 |
2019-10-28 |
Univ California |
Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
|
|
EP3064585B1
(en)
|
2012-12-12 |
2020-02-05 |
The Broad Institute, Inc. |
Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
|
|
US20140271550A1
(en)
|
2013-03-14 |
2014-09-18 |
The Trustees Of The University Of Pennsylvania |
Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune Responses
|
|
WO2014197748A2
(en)
|
2013-06-05 |
2014-12-11 |
Duke University |
Rna-guided gene editing and gene regulation
|
|
CN111218447B
(zh)
|
2013-11-07 |
2024-10-11 |
爱迪塔斯医药有限公司 |
使用统治型gRNA的CRISPR相关方法和组合物
|
|
WO2015138870A2
(en)
|
2014-03-13 |
2015-09-17 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeted epigenetic modification
|
|
CA2953341C
(en)
|
2014-06-25 |
2023-01-24 |
Acuitas Therapeutics Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
GB201418965D0
(enExample)
|
2014-10-24 |
2014-12-10 |
Ospedale San Raffaele And Fond Telethon |
|
|
EP3247328B1
(en)
|
2015-01-21 |
2026-01-07 |
Genevant Sciences Gmbh |
Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
|
|
US11674144B2
(en)
|
2015-04-16 |
2023-06-13 |
California Institute Of Technology |
Fractional regulation of transcription
|
|
EP3929287A3
(en)
|
2015-06-18 |
2022-04-13 |
The Broad Institute, Inc. |
Crispr enzyme mutations reducing off-target effects
|
|
HUE067372T2
(hu)
|
2015-06-29 |
2024-10-28 |
Acuitas Therapeutics Inc |
Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
|
|
JP7059179B2
(ja)
|
2015-10-20 |
2022-04-25 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
遺伝子操作のための方法及び製品
|
|
CN108368028B
(zh)
|
2015-10-28 |
2021-09-03 |
爱康泰生治疗公司 |
用于递送核酸的新型脂质和脂质纳米颗粒制剂
|
|
EP3374494A4
(en)
|
2015-11-11 |
2019-05-01 |
Coda Biotherapeutics, Inc. |
CRISPR COMPOSITIONS AND METHODS OF USE THEREOF FOR GENE THERAPY
|
|
EP3443081A4
(en)
|
2016-04-13 |
2019-10-30 |
Duke University |
CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE
|
|
EP3468612A1
(en)
|
2016-06-09 |
2019-04-17 |
CureVac AG |
Hybrid carriers for nucleic acid cargo
|
|
WO2017212007A1
(en)
|
2016-06-09 |
2017-12-14 |
Curevac Ag |
Cationic carriers for nucleic acid delivery
|
|
CN109688820B
(zh)
|
2016-06-24 |
2023-01-10 |
科罗拉多州立大学董事会（法人团体） |
用于生成条形码化组合文库的方法
|
|
MX2019002004A
(es)
|
2016-08-19 |
2019-10-09 |
Whitehead Inst Biomedical Res |
Metodos para editar la metilacion del adn.
|
|
WO2018049075A1
(en)
|
2016-09-07 |
2018-03-15 |
Flagship Pioneering, Inc. |
Methods and compositions for modulating gene expression
|
|
JP2019532644A
(ja)
*
|
2016-09-30 |
2019-11-14 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Ｒｎａ誘導型核酸修飾酵素及びその使用方法
|
|
WO2018111944A1
(en)
|
2016-12-12 |
2018-06-21 |
Whitehead Institute For Biomedical Research |
Regulation of transcription through ctcf loop anchors
|
|
WO2018147343A1
(en)
|
2017-02-07 |
2018-08-16 |
Edigene Corporation |
Method of treating diseases associated with elevated kras expression using crispr-gndm system
|
|
US11773409B2
(en)
|
2017-04-21 |
2023-10-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
CRISPR/Cas 9-mediated integration of polynucleotides by sequential homologous recombination of AAV donor vectors
|
|
US20230340471A1
(en)
|
2017-04-23 |
2023-10-26 |
Ospedale San Raffaele S.R.L. |
Permanent Epigenetic Gene Silencing
|
|
US11439692B2
(en)
|
2017-05-17 |
2022-09-13 |
Modalis Therapeutics Corporation |
Method of treating diseases associated with MYD88 pathways using CRISPR-GNDM system
|
|
US11072782B2
(en)
|
2017-07-24 |
2021-07-27 |
Albert-Ludwigs-Universitaet Freiburg |
Construct for epigenetic modification and its use in the silencing of genes
|
|
US20190233805A1
(en)
|
2017-10-04 |
2019-08-01 |
The Regents Of The University Of California |
Targetable proteins for epigenetic modification and methods for use thereof
|
|
US11629342B2
(en)
|
2017-10-17 |
2023-04-18 |
President And Fellows Of Harvard College |
Cas9-based transcription modulation systems
|
|
EP3716767A4
(en)
|
2017-10-24 |
2021-11-24 |
Sangamo Therapeutics, Inc. |
METHODS AND COMPOSITIONS FOR TREATMENT OF RARE DISEASES
|
|
WO2019152406A1
(en)
|
2018-01-30 |
2019-08-08 |
The University Of Memphis Research Foundation |
Compositions and methods for regulating a biological process
|
|
AU2019255789B2
(en)
|
2018-04-19 |
2025-11-20 |
The Regents Of The University Of California |
Compositions and methods for gene editing
|
|
US20210284981A1
(en)
|
2018-07-24 |
2021-09-16 |
The Regents Of The University Of California |
Rna-guided nucleic acid modifying enzymes and methods of use thereof
|
|
EP3841205A4
(en)
|
2018-08-22 |
2022-08-17 |
The Regents of The University of California |
VARIANT TYPE V CRISPR/CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF
|
|
EP3840784A4
(en)
|
2018-08-24 |
2022-06-01 |
The Board of Trustees of the Leland Stanford Junior University |
SYSTEMS AND METHODS FOR THE SPATIAL ORGANIZATION OF POLYNUCLEOTIDS
|
|
KR20210069692A
(ko)
|
2018-10-02 |
2021-06-11 |
상가모 테라퓨틱스, 인코포레이티드 |
조작된 유전자 조정제
|
|
JP7618581B2
(ja)
|
2019-04-23 |
2025-01-21 |
サンガモ セラピューティクス， インコーポレイテッド |
９番染色体オープンリーディングフレーム７２遺伝子発現のモジュレーターおよびその使用
|
|
AU2020275884B2
(en)
|
2019-05-16 |
2026-05-14 |
Trustees Of Boston University |
Regulated synthetic gene expression systems
|
|
JP7565620B2
(ja)
|
2019-05-28 |
2024-10-11 |
株式会社モダリス |
Ｄｍｐｋ遺伝子を標的とした筋ジストロフィーの治療方法
|
|
WO2020247883A2
(en)
|
2019-06-07 |
2020-12-10 |
Scribe Therapeutics Inc. |
Deep mutational evolution of biomolecules
|
|
SG11202113253SA
(en)
|
2019-06-07 |
2021-12-30 |
Scribe Therapeutics Inc |
Engineered casx systems
|
|
EP4010004A4
(en)
|
2019-08-07 |
2023-09-13 |
Altius Institute For Biomedical Sciences |
Compositions and methods for modulation of gene expression
|
|
EP4034658A4
(en)
|
2019-09-23 |
2023-11-29 |
Flagship Pioneering Innovations V, Inc. |
MODULATION OF GENOMIC COMPLEXES
|
|
WO2021064913A1
(ja)
|
2019-10-02 |
2021-04-08 |
日本電信電話株式会社 |
映像品質推定装置、映像品質推定方法、及びプログラム
|
|
US20230036273A1
(en)
|
2019-11-27 |
2023-02-02 |
The General Hospital Corporation |
System and method for activating gene expression
|
|
WO2021113772A1
(en)
*
|
2019-12-06 |
2021-06-10 |
Scribe Therapeutics Inc. |
Particle delivery systems
|
|
WO2021133829A1
(en)
|
2019-12-23 |
2021-07-01 |
The Regents Of The University Of California |
Crispr-cas effector polypeptides and methods of use thereof
|
|
CN116234902A
(zh)
|
2020-05-04 |
2023-06-06 |
利兰·斯坦福青年大学托管委员会 |
用于激活和沉默基因表达的效应物结构域的生成、鉴定和表征的组合物、系统和方法
|
|
EP4158009A4
(en)
|
2020-06-02 |
2024-10-02 |
The Regents of the University of California |
Compositions and methods for gene editing
|
|
US20230287391A1
(en)
|
2020-08-14 |
2023-09-14 |
The Governing Council Of The University Of Toronto |
Krab fusion repressors and methods and compositions for repressing gene expression
|
|
WO2022047624A1
(en)
|
2020-09-01 |
2022-03-10 |
Huigene Therapeutics Co., Ltd |
Small cas proteins and uses thereof
|
|
KR20230076820A
(ko)
|
2020-09-01 |
2023-05-31 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
진핵생물 유전체 공학을 위한 합성 미니어처 crispr-cas(casmini) 시스템
|
|
EP4244345A4
(en)
|
2020-11-13 |
2024-10-16 |
Duke University |
TARGETED GENE REGULATION OF HUMAN IMMUNE CELLS USING CRISPR-CAS SYSTEMS
|
|
WO2022114243A1
(en)
|
2020-11-25 |
2022-06-02 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting dmpk gene
|
|
WO2022119957A1
(en)
|
2020-12-02 |
2022-06-09 |
The Regents Of The University Of California |
Crispr-cas effector polypeptides and methods of use thereof
|
|
AU2021392719B2
(en)
|
2020-12-03 |
2025-08-14 |
Scribe Therapeutics Inc. |
Engineered class 2 type v crispr systems
|
|
KR20230129395A
(ko)
|
2020-12-09 |
2023-09-08 |
스크라이브 테라퓨틱스 인크. |
유전자 편집을 위한 aav 벡터
|
|
AU2021409729A1
(en)
|
2020-12-22 |
2023-07-13 |
Nchroma Bio, Inc. |
Compositions and methods for epigenetic editing
|
|
MX2023009036A
(es)
|
2021-02-01 |
2023-10-30 |
Epsilen Bio S R L |
Silenciamiento de genes.
|
|
WO2022261150A2
(en)
|
2021-06-09 |
2022-12-15 |
Scribe Therapeutics Inc. |
Particle delivery systems
|
|
JP2024526895A
(ja)
|
2021-07-20 |
2024-07-19 |
エピクリスパー バイオテクノロジーズ， インコーポレイテッド |
標的遺伝子を調節するための系および方法
|
|
WO2023023553A2
(en)
|
2021-08-17 |
2023-02-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions, systems, and methods for activating and silencing gene expression
|
|
CA3228222A1
(en)
|
2021-09-08 |
2023-03-16 |
Brian C. Thomas |
Class ii, type v crispr systems
|
|
IL311610A
(en)
|
2021-09-21 |
2024-05-01 |
Scribe Therapeutics Inc |
Engineered CASX suppressor systems
|
|
EP4405490A2
(en)
|
2021-09-23 |
2024-07-31 |
Scribe Therapeutics Inc. |
Self-inactivating vectors for gene editing
|
|
WO2023055893A1
(en)
|
2021-09-30 |
2023-04-06 |
Peter Biotherapeutics, Inc. |
Gene regulation
|
|
EP4437092A1
(en)
|
2021-11-26 |
2024-10-02 |
Epigenic Therapeutics Inc. |
Method of modulating pcsk9 and uses thereof
|
|
CN116497002A
(zh)
|
2022-01-19 |
2023-07-28 |
中国科学院动物研究所 |
工程化的CasX核酸酶、效应蛋白及其用途
|
|
CA3254504A1
(en)
|
2022-03-04 |
2023-09-07 |
Epigenic Therapeutics Pte. Ltd. |
GENOME COMPOSITION AND EDITING METHODS
|
|
WO2023173110A1
(en)
|
2022-03-11 |
2023-09-14 |
Epicrispr Biotechnologies, Inc. |
Compositions, systems, and methods for treating familial hypercholesterolemia by targeting pcsk9
|
|
EP4493700A2
(en)
|
2022-03-17 |
2025-01-22 |
The Board of Trustees of the Leland Stanford Junior University |
Compositions and methods for modulating alpha-synuclein expression
|
|
CN119836432A
(zh)
|
2022-05-01 |
2025-04-15 |
恩科洛玛生物公司 |
用于pcsk9表达的表观遗传调节的组合物和方法
|
|
CA3257824A1
(en)
|
2022-06-02 |
2023-12-07 |
Scribe Therapeutics Inc. |
MODIFIED TYPE V, CLASS 2 CRISPR SYSTEMS
|
|
CN119998446A
(zh)
|
2022-06-07 |
2025-05-13 |
斯克里贝治疗公司 |
用于靶向pcsk9的组合物和方法
|
|
CN114921439B
(zh)
|
2022-06-16 |
2024-04-26 |
尧唐(上海)生物科技有限公司 |
CRISPR-Cas效应子蛋白、其基因编辑系统及应用
|
|
KR20250059560A
(ko)
|
2022-06-23 |
2025-05-02 |
크로마 메디슨, 인크. |
후성유전학적 편집을 위한 조성물 및 방법
|
|
WO2023250148A1
(en)
|
2022-06-23 |
2023-12-28 |
Chroma Medicine, Inc. |
Compositions and methods for epigenetic editing
|
|
CA3260237A1
(en)
|
2022-06-24 |
2023-12-28 |
Tune Therapeutics, Inc. |
Compositions, systems and methods for reducing low-density lipoprotein by targeted gene repression
|
|
CA3260110A1
(en)
|
2022-06-24 |
2023-12-28 |
European Molecular Biology Laboratory |
MODULAR TOOL BASED ON CRISPR FOR THE SPECIFIC INTRODUCTION OF EPIGENETIC MODIFICATIONS ON TARGET LOCI
|
|
WO2024032681A1
(zh)
|
2022-08-11 |
2024-02-15 |
益杰立科(上海)生物科技有限公司 |
一种表观编辑靶点的方法及用途
|
|
KR20250128349A
(ko)
|
2022-12-23 |
2025-08-27 |
에피제닉 테라퓨틱스 피티이 리미티드 |
융합체 및 이의 용도
|
|
WO2024206620A1
(en)
|
2023-03-29 |
2024-10-03 |
Scribe Therapeutics Inc. |
Messenger rna encoding casx
|
|
TW202444914A
(zh)
|
2023-03-29 |
2024-11-16 |
美商斯奎柏治療公司 |
抑制子融合蛋白系統
|
|
WO2024206555A1
(en)
|
2023-03-29 |
2024-10-03 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of pcsk9
|